OmniAb Valuation Multiples

OmniAb Overview

About OmniAb

OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Founded

2012

HQ

Employees

114

Website

omniab.com

Sectors

BiopharmaceuticalsLife Sciences ToolsBioTech

Financials (LTM)

Revenue: $21M

EBITDA: ($43M)

EV

$210M

Valuation Multiples

Multiples.vc

Start free trial

OmniAb Financials

OmniAb reported last 12-month revenue of $21M and negative EBITDA of ($43M).

In the same LTM period, OmniAb generated $20M in gross profit, ($43M) in EBITDA losses, and had net loss of ($62M).

OmniAb P&L

In the most recent fiscal year, OmniAb reported revenue of $19M and EBITDA of ($45M).

OmniAb expects next 12-month revenue of XXX and NTM EBITDA of XXX

OmniAb Stock Performance

OmniAb has current market cap of $248M, and enterprise value of $210M.

OmniAb's stock price is $1.73.

OmniAb Valuation Multiples

OmniAb trades at 10.2x EV/Revenue multiple, and (4.9x) EV/EBITDA.

OmniAb Financial Valuation Multiples

As of March 21, 2026, OmniAb has market cap of $248M and EV of $210M.

Equity research analysts estimate OmniAb's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

OmniAb has a P/E ratio of (4.0x).

OmniAb Margins & Growth Rates

OmniAb's revenue in the last 12 month grew by 54%.

OmniAb's revenue per employee in the last FY averaged $0.2M.

OmniAb's rule of 40 is (154%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

OmniAb's rule of X is (73%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

OmniAb Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Life Sciences Tools comps.

OmniAb M&A Activity

OmniAb acquired XXX companies to date.

Last acquisition by OmniAb was on XXXXXXXX, XXXXX. OmniAb acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

OmniAb Investment Activity

OmniAb invested in XXX companies to date.

OmniAb made its latest investment on XXXXXXXX, XXXXX. OmniAb invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).